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Abstract
Lemur tyrosine kinase 3 (LMTK3) is an oncogenic kinase that is involved in different types of cancer (breast, lung, gastric,
colorectal) and biological processes including proliferation, invasion, migration, chromatin remodeling as well as innate and
acquired endocrine resistance. However, the role of LMTK3 in response to cytotoxic chemotherapy has not been
investigated thus far. Using both 2D and 3D tissue culture models, we found that overexpression of LMTK3 decreased the
sensitivity of breast cancer cell lines to cytotoxic (doxorubicin) treatment. In a mouse model we showed that ectopic
overexpression of LMTK3 decreases the efﬁcacy of doxorubicin in reducing tumor growth. Interestingly, breast cancer cells
overexpressing LMTK3 delayed the generation of double strand breaks (DSBs) after exposure to doxorubicin, as measured
by the formation of γH2AX foci. This effect was at least partly mediated by decreased activity of ataxia-telangiectasia
mutated kinase (ATM) as indicated by its reduced phosphorylation levels. In addition, our RNA-seq analyses showed that
doxorubicin differentially regulated the expression of over 700 genes depending on LMTK3 protein expression levels.
Furthermore, these genes were found to promote DNA repair, cell viability and tumorigenesis processes / pathways in
LMTK3-overexpressing MCF7 cells. In human cancers, immunohistochemistry staining of LMTK3 in pre- and post-
chemotherapy breast tumor pairs from four separate clinical cohorts revealed a signiﬁcant increase of LMTK3 following
both doxorubicin and docetaxel based chemotherapy. In aggregate, our ﬁndings show for the ﬁrst time a contribution of
LMTK3 in cytotoxic drug resistance in breast cancer.
Introduction
Lemur tyrosine kinase 3 (LMTK3; also known as LMR3,
TYKLM3, KIAA1883) is a predicted dual-speciﬁcity protein
kinase whose expression levels has been implicated in
cancer cell invasion, endocrine resistance, poor prognosis
and overall tumor progression in different types of malig-
nancies [1–15]. Based on previous observations associating
LMTK3 with tamoxifen resistance in breast cancer [1, 12],
we set out to investigate a possible role of LMTK3 in breast
cancer cells’ response to cytotoxic treatment in vitro and
in vivo.
Adjuvant and neo-adjuvant chemotherapy still represent
the backbone of systemic treatment for many cancers at
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both the early and advanced stages of the disease [16–18].
DNA-damaging agents are used in cancer chemotherapy, as
DNA integrity is crucial for proper cellular function and
proliferation [19, 20]. One of these drugs is doxorubicin, an
anthracycline antibiotic, which intercalates into DNA, hin-
dering topoisomerase II progression and leading to
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cytotoxicity mostly by inhibition of DNA replication and
generation of double-strand breaks (DSBs). However, even
though doxorubicin is a widely used drug in chemotherapy
regimen for breast cancer patients [21], resistance (innate
and/or acquired) is often observed [22]. Therefore, cellular
mechanisms that relate to doxorubicin-related resistance
need deciphering.
As mentioned above, inhibition of topoisomerase II by
doxorubicin results in the formation of DNA DSBs [23, 24].
Ataxia-telangiectasia mutated kinase (ATM) is amongst the
earliest kinases activated in the cellular response to DSBs
[25, 26]. In addition, it has been shown that ATM kinase
can be activated upon doxorubicin treatment [27–29]. This
is achieved by the phosphorylation at Ser1981 leading to
the dissociation of inactive ATM dimers and the generation
of catalytically active monomers that later expose ATM
kinase activity at the DSBs sites [30, 31].
Several studies have demonstrated that doxorubicin-
induced DNA DSBs lead to the phosphorylation of histone
H2AX at Ser139 via ATM [26, 32–35]. Histone H2AX is a
substrate of several phosphatidylinositol 3-kinase-related
kinases, such as ATM, ATM-and Rad3-related kinase
(ATR) as well as DNA-dependent protein kinase. It has
been described that phosphorylation of histone H2AX on
Ser139 (γH2AX) represents the most frequent marker of the
DNA damage response caused by DSBs [35–37], while the
number of foci formation is proportional to the severity of
the damage [38]. KRAB-associated protein 1 (KAP1) is
another ATM substrate identiﬁed as a co-repressor of gene
transcription. Doxorubicin-mediated ATM activation elicits
phosphorylation of KAP1 at Ser824 and inhibits
KAP1 sumoylation. Subsequently, ATM-dependent KAP1
Ser824 phosphorylation de-represses transcription of p21,
Gadd45α, Bax, Puma and Noxa that promote cell cycle
control and apoptosis in response to doxorubicin [27, 28].
In this study, we implicate LMTK3 in the protection of
breast cancer cells from DNA DSBs as induced by
doxorubicin. Using 2D monolayers as well as 3D-spheroids
cultures we show that breast cancer cells stably over-
expressing LMTK3 are more resistant to doxorubicin
treatment when compared to the parental ones. Importantly,
we underpin these results by using a breast cancer xenograft
mouse model revealing that increased LMTK3 levels
decrease the antitumor activity of doxorubicin.
Furthermore, we provide details underlying the effects of
LMTK3 in doxorubicin induced DNA damage/repair pro-
cesses. We demonstrate that MCF7 cells stably over-
expressing LMTK3 delay H2AX Ser139 phosphorylation
resulting in fewer γH2AX foci as compared to parental
MCF7 cells. Our analysis also reveals that ectopic expres-
sion of LMTK3 delays DNA damage response by
decreasing ATM phosphorylation.
To obtain information underlying the LMTK3-mediated
doxorubicin resistance, we employed a whole genome
transcriptomic analysis approach using RNA-sequencing
(RNAseq). A plethora of bioinformatics analyses tools were
implemented including DESeq2 (differential gene expres-
sion), the ingenuity pathway analysis (IPA; canonical
pathways and disease/biological functions), the STRING
database (protein–protein interaction analysis), and the
Gene Ontology Enrichment Analysis (protein functions). As
a result, we identiﬁed several genes and pathways that are
differentially regulated by doxorubicin based on LMTK3
expression. In particular, we observed that doxorubicin
treatment of LMTK3-overexpressing MCF7 cells shows a
decrease in DNA damage sensing compared to parental
MCF7 cells, while pathways involved in cell survival, cell
viability and tumorigenesis are predominantly activated.
Finally, we examined the expression of LMTK3 in 148
pairs of primary breast cancer cases, before and after
receiving chemotherapy. Interestingly, we detected a sig-
niﬁcant upregulation of LMTK3 protein levels, as assessed
by immunohistochemistry, following doxorubicin and
docetaxel based therapy. These results suggest that the
ultimate resistance observed to these drugs could also be
due to the aberrant over-expression of oncogenic LMTK3.
In summary, our data illustrate a novel role and involvement
of LMTK3 in doxorubicin resistance in breast cancer.
Results
Ectopic expression of LMTK3 decreases the cytotoxic
efﬁcacy of doxorubicin in vitro and in vivo
To study the physiological role of LMTK3 in response to
chemotherapeutic drug treatment, MCF7 and MCF7/
LMTK3 cells grown either in 2D or 3D cultures were
treated with various doses of doxorubicin for different time
points. The effects of LMTK3 overexpression on
Fig. 1 Over-expression of LMTK3 impedes the effectiveness of
doxorubicin in vitro and in vivo. Following treatment with different
concentrations of doxorubicin (0.05, 0.1, and 0.2 μM) for 72 h, the
percentage (%) of cell viability, was assessed by CellTiter-Glo assay in
MCF7 and MCF7/LMTK3 cells cultured in either (a) 2D (monolayers)
or (b) 3D (spheroids). All error bars represent the mean ± the standard
deviation (SD) from three independent experiments. c Quantiﬁcation
in primary tumor size between MCF7 and MCF7/LMTK3 xenografts
with or without doxorubicin treatment at Day 28. (Left) The means and
the error bars show the standard error of the mean (SEM) for ten
MCF7-LMTK3, nine MCF7-LMTK3+Dox, ten MCF7 and seven
MCF7+Dox –derived xenografts. (Right) Data are displayed as indi-
vidual data points together with their corresponding median values. d
Representative images of tumors at Day 28 are shown for the different
groups. (e) Histological analysis of LMTK3 and Ki67 expression in
representative tumor tissue sections of MCF7 and MCF7/LMTK3
tumors (no doxorubicin treatment). Original magniﬁcation, 100×.
Scale bars, 100 μm. (**P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001)
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doxorubicin sensitivity, were assessed by cell viability and
proliferation assays. MCF7/LMTK3 cells grown either in
2D (Fig. 1a and Supplementary Figure 1A, B) or 3D (Fig.
1b) were more resistant to doxorubicin-induced cytotoxi-
city, compared to the parental MCF7. Similarly, MDA-MB-
231/LMTK3 cultured in 3D (Supplementary Figure 1C),
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displayed higher viability rates following doxorubicin
treatment vs. the parental MDA-MB-231 cells, while the
opposite results were observed when this cell line was
cultured in 2D monolayer (Supplementary Figure 1D). As
cells’ behavior is altered in 3D vs. 2D cultures, this result
suggests that the actions of LMTK3 in MDA-MB-231
(triple negative cell line) may be inﬂuenced by various
intrinsic and/or extrinsic factors as well as tissue archi-
tecture. The latter parameter is particularly important for
breast cells as it has been shown that lactation stops when
milk-secreting cells are cultured in 2D, while this feature is
restored once cells are cultured in 3D [39–41]. In addition,
as expected, treatment with doxorubicin in all cell lines was
more active in 2D vs. 3D cultures [42–44]. Taken together,
these data indicate that breast cancer cells overexpressing
LMTK3 are less sensitive (or more resistant) to doxorubicin
treatment, compared to their respective parental cell lines
expressing basal levels of LMTK3.
To evaluate the impact of LMTK3 in the antitumor
efﬁcacy of doxorubicin in vivo, female athymic nude
mice in a xenograft tumor model. MCF7 and MCF7/
LMTK3 cells were subcutaneously injected into the right
ﬂank of mice. On day 10, animals were randomized in
different groups and doxorubicin was administered
intravenously to the respective groups on the same day
and one week later (Group 1: MCF-7; Group 2: MCF7
+Dox; Group 3: MCF7/LMTK3; Group 4: MCF7/
LMTK3+Dox). Tumor volume was determined in vivo
by external caliper on the indicated time points. On day
28, mice were sacriﬁced and tumors were dissected and
photographed. As anticipated, LMTK3 overexpression
increased tumor growth, as previously observed in an
in vivo study using T47D and T47D/LMTK3 breast
cancer cell lines [13] further supporting its oncogenic
role. In addition, doxorubicin treatment signiﬁcantly
inhibited tumor growth in both the MCF7 and the MCF7/
LMTK3 xenograft mice. However, in the presence of
doxorubicin, the tumor growth inhibition was reduced in
the MCF7/LMTK3 group (P= 0.0022) compared to the
MCF7 one (P < 0.0001) (Figs. 1c, d and Supplementary
Figure 2), data that were in line with our in vitro results
above. Finally, LMTK3 overexpression was also asso-
ciated with increased tumor cell proliferation as assessed
by Ki-67 immunohistochemistry analysis. As shown in
the representative images (Fig. 1e), abundant Ki67-
positive nuclei were observed mostly in the tumors of
the MCF7/LMTK3 mice compared to the MCF7 ones.
LMTK3 over-expression delays doxorubicin-induced
DNA DSBs
Exposure to doxorubicin generates DSBs, leading to the
phosphorylation of histone H2AX on Ser139. The
γH2AX formation is a major, rapid and sensitive marker
of DSB induction [45]. Hence, to further explore the
doxorubicin-resistant phenotype of LMTK3 over-
expressing cells, we examined the time dependency of
γH2AX foci formation following doxorubicin treatment
by immunoﬂuorescence
MCF7 and MCF7/LMTK3 cells were exposed to 0.4 μM
of doxorubicin and incubated for 12, 24, and 48 h.
Untreated cells contained few γH2AX foci per cell (8.8 ±
1.21 foci in MCF7, 11.8 ± 2.01 in MCF7/LMTK3; Fig. 2a)
with no statistically signiﬁcant difference between the two
cell lines. As expected, H2AX phosphorylation was
increased in a time-dependent manner upon doxorubicin
exposure compared to the respective untreated cells. Inter-
estingly, γH2AX accumulation was signiﬁcantly lesser in
MCF7/LMTK3 cells as compared to the MCF7 ones, at
various time points during doxorubicin exposure as
demonstrated by western blot and immunoﬂuorescence
analyses (Figs. 2b, c and Supplementary Figure 3). These
results suggest that LMTK3 may attenuate DNA damage by
Fig. 2 Overexpression of LMTK3 delays doxorubicin-induced DNA
DSBs and affects the phosphorylation of ATM. a MCF7 and MCF7/
LMTK3 cells were treated with 0.4 µM of doxorubicin and 12, 24, and
48 h later, quantitative analysis of γH2AX foci was performed. All
error bars represent the mean ± SEM (50 cells were analyzed per each
time point; ****P ≤ 0.0001). b Western blot analysis for endogenous
γH2AX levels in MCF7 and MCF7/LMTK3 cells following doxor-
ubicin treatment for different time points. β-actin was used as loading
control. c MCF7 and MCF7/LMTK3 cells were ﬁxed and subjected to
confocal immunoﬂuorescence analysis. Representative confocal
microscopy images for γH2AX and LMTK3 are shown for different
time points. d MCF7 and MCF7-LMTK3 cells were treated with 1 µM
of doxorubicin for up to 2 h. Following, the media was removed
allowing cells to grow in fresh complete media for another 10 h.
Quantitative analysis of γH2AX foci was performed. All error bars
represent the mean ± SEM (50 cells were analysed per each time point;
**P ≤ 0.01). e MCF7 and MCF7/LMTK3 cells were ﬁxed and sub-
jected to confocal immunoﬂuorescence analysis. Representative con-
focal microscopy images for γH2AX are shown for different time
points following doxorubicin release. f Doxorubicin-induced DNA
damage measured by neutral comet assay. MCF7 and MCF7-LMTK3
cells were treated with 1 µM of doxorubicin for up to 2 h. Following,
the media was removed allowing cells to grow in fresh complete media
for another 6 and 24 h. Cells were analyzed by ﬂuorescence micro-
scopy; The tail moment was quantiﬁed using the ImageJ software with
OpenComet plug-in. All error bars represent the mean ± SEM (51 cells
were analysed per each time point; ***P ≤ 0.001; ****P ≤ 0.0001). A
representative western blot of LMTK3 expression in MCF7 and
MCF7/LMTK3 cell lines is shown. g MCF7 and MCF7-LMTK3 cells
were treated with 1 µM of doxorubicin for 2, 4, 8, 16, and 24 h.
Western blot analysis was performed using the respective antibodies.
β-actin was used as loading control. Representative results and quan-
tiﬁcation of protein bands using ImageJ software are shown for two
separate blots. h MCF7 and MCF7-LMTK3 cells were treated with 1
µM of doxorubicin for 15 min, 30 min, 1, 2, and 4 h. Western blot
analysis was performed using the respective antibodies. β-actin was
used as loading control. Representative results and quantiﬁcation of
protein bands using ImageJ software are shown for two separate blots
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playing a role in the formation of DSBs as determined by
the phosphorylation of the histone variant H2AX.
We then sought to determine whether the rapid resolution
in γH2AX foci formation at 12, 24 or 48 h was due to
delayed resolution of damage or increased induction of
DNA repair, foci were quantiﬁed at earlier time points.
Following 2 h of doxorubicin treatment (1 µM), to induce
DNA damage, the drug was removed and cells continued
being cultured in fresh complete media for additional 10 h.
The γH2AX kinetics followed a biphasic curve; ﬁrst, a rapid
phase of foci formation followed by an exponential γH2AX
foci decay phase. Although the initial number of foci was
nearly identical in both MCF7 and MCF7/LMTK3 cells at
30 min, indicating similar levels of induced DNA damage,
the number of foci present 120 min after doxorubicin
treatment was clearly lower in MCF7-LMTK3 cells (35.98
± 1.57) compared to MCF7 cells (51.42 ± 1.64) (Fig. 2d). In
addition, LMTK3 over-expression delayed this response as
the foci increased gradually and culminated at 180 min
(48.58 ± 1.48). However, despite the time shift (~60 min) in
the peaks observed in MCF7 and MCF7/LMTK3, there was
no statistically signiﬁcant difference between the peaks of
the two cell lines (MCF7: 51.42 ± 1.64 vs. MCF7/LMTK3:
48.58 ± 1.48). Interestingly, although the decay curve
appears similar, analysis of the time course for the dis-
appearance of foci in MCF7 and MCF7/LMTK3 cells
after exposure to doxorubicin showed that the foci in
MCF7/LMTK3 cells disappeared more rapidly, compared
with that observed in MCF7 cells. In the case of MCF7
cells, 10 h post γH2AX foci peak formation, the number
of foci reduced ~52% (from 51.42 ± 1.64 to 24.44 ± 1.35).
In the case of MCF7/LMTK3 cells, 9 h after γH2AX foci
peak formation the number of foci reduced ~62% (from
48.58 ± 1.48 to 18.32 ± 1.15) (Figs. 2d, e and Supple-
mentary Table 1).
Finally, we used comet assays (single-cell gel electro-
phoresis) that can detect a variety of DNA damage (single
or DSBs and DNA crosslinks) as well as for monitoring
DNA repair [46, 47]. Cells were treated with 1 µM of
doxorubicin for 2 h to induce DNA breaks. Following, the
media was replaced with fresh one allowing cells to grow
for another 6 and 24 h. Doxorubicin caused the “comet”
migration pattern characteristics, while quantitative analysis
showed that overexpression of LMTK3 (MCF7/LMTK3)
led to signiﬁcantly lower DNA tail moments when com-
pared to MCF7 cells (12.89 ± 1.10 vs. 21.71 ± 1.35 for 6 h
(P < 0.0001) and 8.49 ± 0.80 vs. 12.10 ± 1.00 for 24 h (P=
0.0043)) (Fig. 2f and Supplementary Table 2), which is
consistent with the reduced γH2AX foci observed in our
previous experiments. Collectively, these data demonstrate
that LMTK3 has a role in delaying doxorubicin-induced
DNA damage and is potentially involved in the DNA repair
mechanisms.
LMTK3 impedes γH2AX foci formation by
inﬂuencing the activity of ataxia-telangiectasia
mutated kinase (ATM)
Next, the effects of LMTK3 overexpression on ATM were
evaluated. MCF7 and MCF7/LMTK3 cells were exposed to
doxorubicin for up to 24 h and ATM phosphorylation status
was examined. Consistent with previous reports [27, 28],
ATM phosphorylation at Ser1981 in MCF7 cells, peaked
within 2–4 h of exposure to doxorubicin and was gradually
decreased over time before reaching its basal levels 16 h
later. In contrast, MCF7/LMTK3 cells displayed weaker
total ATM phosphorylation compared to MCF7, while the
signal appeared highest after 4 h of doxorubicin treatment
and decayed faster (~8 h of doxorubicin treatment) (Fig.
2g). Since ATM is involved in the early DNA damage
response, cells were treated and harvested at shorter time
points. Similarly, phosphorylation of ATM at Ser1981 in
MCF7/LMTK3 cells was lesser in the initial 2 h of doxor-
ubicin treatment compared to MCF7 (Fig. 2h). Finally, we
also checked for the phosphorylation of KAP1, which
represents a novel ATM substrate that is involved in DNA
damage [28]. In MCF7/LMTK3 cells, phosphorylation of
KAP1 at Ser824, after 2 h of doxorubicin treatment, was
less than half as compared to MCF7 cells, following a
similar pattern with the activation of ATM (Fig. 2h). Taken
together, these data imply that over-expression of LMTK3
may delay the sensing to DNA damage through the ATM
signaling pathway.
Doxorubicin differentially regulates global
transcriptome changes based on LMTK3 status
To gain additional insights into the molecular mechanisms
and pathways involved in LMTK3 mediated chemo-resis-
tance, we performed transcriptome proﬁling by RNA-seq in
MCF7 and MCF7/LMTK3 cells treated with 1 μM of
doxorubicin for 24 h or vehicle only (DMSO; control).
Principal component analysis (PCA) and sample clustering
analysis of the RNA-Seq data showed a high degree of
similarity between replicate samples (Supplementary Figure
4A and B). Interestingly, the PCA plot revealed a greater
doxorubicin-mediated transcriptomic variation in MCF7/
LMTK3 cells in comparison to MCF7 cells (Supplementary
Figure A). This suggests a potential interaction between
LMTK3 and doxorubicin pathways in MCF7 cells.
We next employed the differential gene expression ana-
lysis using the DESeq2 pipeline to identify genes induced
by doxorubicin in MCF7 and MCF7/LMTK3 cells. In
summary, a total of 9368 and 6988 transcripts were detected
to be signiﬁcantly regulated by doxorubicin in MCF7 and
MCF7/LMTK3 respectively (Fig. 3a and Supplementary
excel ﬁles 1 & 2). Approximately, 25% of doxorubicin
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regulated transcripts were unique to either MCF7 or MCF7/
LMTK3, hence, providing further evidence for differential
gene regulation by doxorubicin based on expression levels
of LMTK3. To gain additional insights into similarities and
differences in doxorubicin effect, we plotted (Venn dia-
gram) genes identiﬁed to be regulated by doxorubicin either
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in MCF7 or MCF7/LMTK3 cells at the false discovery rate
Padj < 0.05 and Log2 fold difference of ≥|1|. We found that
doxorubicin treatment upregulated 4957 and 3813 tran-
scripts and downregulated 4411 and 3175 transcripts in
MCF7 and MCF7/LMTK3 cells respectively (Fig. 3b and
Supplementary excel ﬁles 1 & 2). Of these transcripts, 3304
and 2786 genes were commonly regulated, and 3276 and
896 were uniquely regulated by doxorubicin in MCF7 and
MCF7/LMTK3 respectively. Moreover, we also generated
heatmaps displaying the amounts by which the read-counts
of the top-30 genes identiﬁed as uniquely or commonly
regulated by doxorubicin across MCF7 and MCF7/LMTK3
cells deviate from the genes’ average across all the samples
(Figs. 3c, d and Supplementary excel ﬁle 3). To validate our
results, we performed qRT-PCR analysis in 14 randomly
picked genes, including SOX6 and HEY1 that were pre-
dicted to be differentially expressed. We found a strong
validation (14/14) of our RNAseq and DESeq2 analysis in a
separate cohort of samples (Supplementary Tables 3 & 4).
We did observe a difference in the fold-difference as cal-
culated by DESEq2 and the qRT-PCR technique. However,
this is expected as fold-difference predicted by DESEq2
accounts for reads aligning to the entire gene, while qRT-
PCR is less sensitive as it is based on a deﬁned region
(ampliﬁed by primer set) within the gene.
Our Venn diagram also pointed to an intriguing result
where doxorubicin differentially regulated the expression of
SOX6 and HEY1 transcription factors in MCF7 and MCF7/
LMTK3 cells (Fig. 3e). In particular, doxorubicin sup-
pressed the expression of SOX6 in MCF7 cells (~ 6-fold),
whereas it increased it in MCF7/LMTK3 cells (~4-fold). In
contrast, doxorubicin potentiated the expression of HEY1
by ~3 × fold in MCF7 cells and suppressed it by ~2 × fold in
MCF7/LMTK3 (Fig. 3e).
To further inquire if there were additional genes that
differentially responded to doxorubicin treatment between
MCF7 and MCF7/LMTK3 cells (from now on labelled as:
Dox:LMTK3 genes), we re-analyzed the RNA-Seq data
using the interaction model provided by DESeq2. This
model tests for genes that respond differently to doxorubicin
treatment across MCF7 and MCF7/LMTK3 by controlling
for differences between cell lines due to LMTK3 over-
expression and doxorubicin treatment effect on MCF7 cells.
The model identiﬁed that 896 genes responded differently
(at the Padj < 0.05 and Log2 fold difference of ≥1 or ≤−1) to
doxorubicin treatment in MCF7 and MCF7/LMTK3 cells
(Fig. 4a and Supplementary excel ﬁle 4). To further dis-
tinguish these genes from those regulated commonly by
doxorubicin in both cell lines, we plotted the Log2 fold
expression changes vs. Log10 P-values and cataloged genes
according to their mode of regulation (Figs. 4b, c). More-
over, we generated heatmaps displaying the amounts by
which the read-count of the top-30 Dox:LMTK3 genes
deviate from the genes’ average across all the samples (Fig.
4d).
Next, to understand how LMTK3 overexpression affects
doxorubicin-mediated gene expression we compared and
contrasted expression of Dox:LMTK3 genes across all the
samples using the intersection UpSet plot (Fig. 4e). This
revealed an interesting antagonistic regulation of 784 genes
by doxorubicin in MCF7 and MCF7/LMTK3 cells (Fig. 4e;
red lines). We found that when compared to doxorubicin-
treated MCF7 cells, doxorubicin-treatment in MCF7/
LMTK3 cells had a signiﬁcantly lower (Padj ≤ 0.05 and
Log2 fold ≤−1) upregulation and downregulation of 184
and 600 transcripts, respectively. Furthermore, the plot
revealed a small synergistic effect between LMTK3 over-
expression and doxorubicin-mediated regulation of 26
genes (Fig. 4e; blue lines). In comparison to doxorubicin-
treated MCF7, we found a signiﬁcantly higher (Padj ≤ 0.05
and Log2 fold ≥ 1) downregulation and upregulation of 9
and 15 transcripts respectively in MCF7/LMTK3 cells.
Functional analysis of doxorubicin mediated
differential gene expression
One of the most interesting RNAseq analysis observations
was related to functional pathways that were differently
altered in doxorubicin-treated MCF7 and MCF7/LMTK3
cells. We employed the IPA algorithm, which compares
observed gene expression changes in our dataset with what
is known from the current literature, to predict alterations in
canonical pathways, biological functions, and upstream
regulatory molecules. Using IPA, we found several path-
ways including estrogen-mediated S-phase entry, basal cell
carcinoma signaling, osteoarthritis pathway, and
P53 signaling that were either inhibited or had a trend
towards inhibition (based on Z score) in doxorubicin-treated
MCF7/LMTK3 cells compared to doxorubicin-treated
MCF7 cells. In contrast, pathways such as mitotic roles of
Polo-like kinase, Rac signaling, aryl hydrocarbon receptor
Fig. 3 Global transcriptomic alterations induced by doxorubicin in
MCF7 and MCF7/LMTK3 cells. a Venn diagram showing a high
degree of overlap as well as differences in the transcripts signiﬁcantly
regulated by doxorubicin in MCF7 and MCF7/LMTK3 cells (Padj <
0.05 and Log2 fold difference of ≥|1|). b Venn diagram comparing
numbers of transcripts signiﬁcantly up (UP) or down-regulated (DW)
in each dataset. c Heatmaps showing top-30 (ordered based on Padj
value) exclusively regulated transcripts upon doxorubicin treatment of
MCF7 and MCF7/LMTK3 cells. Downregulated transcripts (DW) are
shown in the upper panel, while upregulated transcripts (UP) are
shown in the lower panel. d Heatmap showing amounts by which the
read counts of the top-30 (ordered based on Padj value) commonly
regulated genes deviates from the gene’s average across all the sam-
ples. e Count plot comparing the changes in the RNA-seq read counts
of HEY1 and SOX6 between MCF7 and MCF7/LMTK3 cells upon
treatment with DMSO or 1 μM doxorubicin
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signaling, GM-CSF signaling, and CD40 signaling were
activated or had a trend towards activation in doxorubicin-
treated MCF7/LMTK3 cells compared to MCF7 (Fig. 5a
and Supplementary excel ﬁle 5). The IPA also revealed a
signiﬁcant decrease in doxorubicin-mediated inhibition of
several biological functions including cell survival, cell
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viability of tumor cells and DNA repair, as well as, a sig-
niﬁcant decrease in doxorubicin-mediated activation of
biological functions such as cell death of tumor cells, the
formation of γH2AX and chromosomal instability in
doxorubicin-treated MCF7/LMTK3 cells compared to
doxorubicin-treated MCF7 cells (Fig. 5b and Supplemen-
tary excel ﬁle 6).
Furthermore, using IPA we found ﬁve upstream reg-
ulators including ESR1 (P= 3.87 × 10−7), NUPR1 (P=
2.95 × 10−4), Rb (P= 0.00595), BRD4 (P= 0.0123), and
miR-16-5p (P= 0.0207) whose downstream target genes
responded differently to doxorubicin treatment of MCF7
(Supplementary excel ﬁle 7) and MCF/LMTK3 (Supple-
mentary excel ﬁle 8) cells. These upstream regulators may
offer an explanation for why doxorubicin had a different
effect on gene expression in MCF7 and MCF7/LMTK3
cells (Supplementary Figure 5). Furthermore, we also per-
formed an upstream regulator analysis with Dox:LMTK3
genes (Supplementary excel ﬁle 9).
Clustering the Dox:LMTK3 genes based on their protein
functions can offer a distinctive insight into the how cellular
activities differ in doxorubicin-treated MCF7 and MCF7/
LMTK3 cells. Therefore, we ﬁrst identiﬁed the PANTHER
protein class of Dox:LMTK3 genes (Fig. 5c, Supplementary
excel ﬁle 10). Next, we found three clusters of functionally
interacting proteins using the fast-greedy algorithm in R.
We then performed three separate GO enrichment analyses
for proteins enriched in each cluster and ﬁnally mapped
STRING protein networks for Dox:LMTK3 proteins enri-
ched in interesting pathways (Figs. 5d, e, f). Our analyses
revealed that a vast majority of Dox:LMTK3 genes syn-
thesized nucleic acid binding proteins, transcription factors
and enzyme modulators. Furthermore, the clustering and
GO enrichment analyses identiﬁed proteins enriched in
pathways known to be associated with doxorubicin treat-
ment such as transcription regulation [48], double-stranded
break repair, DNA repair [49] and cellular apoptosis [50]
(Figs. 5d, e, f and Supplementary excel ﬁles 11–13). Intri-
guingly, the analysis also identiﬁed pathways such as
mRNA processing, cell-adhesion, and chromatin remodel-
ing that were not expected to be differentially regulated by
doxorubicin in MCF7 and MCF7/LMTK3 cells. Taken
together, the RNAseq data revealed dysregulation within
the canonical pathways, biological functions, protein inter-
action and upstream regulators that offer additional insight
into the observed doxorubicin resistance in MCF7/LMTK3
cells.
Breast cancer chemotherapy affects LMTK3
expression levels
Lastly, we examined the expression levels of LMTK3 in
148 breast cancer patients from 4 individual studies, pre and
post-chemotherapy treatment. Representative immunohis-
tochemistry staining of LMTK3 expression is shown in Fig.
6a. When data from all four studies were pooled, a sig-
niﬁcant increase in LMTK3 expression with chemotherapy
was observed (mean LMTK3 expression 150.2 ± 84.4 vs.
114.8 ± 87.2 for post cycle 1 vs. pre-treatment; P= 0.001)
(Fig. 6b). Interestingly, when data from studies 1 and 4,
where 3 serial pre and post-treatment tumor biopsies were
obtained from each patient, were pooled, progressive
increase in tumor LMTK3 expression was noted with
increasing number of chemotherapy cycles (mean LMTK3
expression 67.6 ± 74.9, 94.6 ± 96.0, 135.1 ± 108.1 for pre,
post cycle 1, and post cycle 4-chemotherapy, P= 0.006 for
post cycle 1 vs. baseline, P= 0.020 for post cycle 4 vs.
baseline).
Discussion
We and others have demonstrated that LMTK3 expression
is signiﬁcantly elevated in high-grade breast tumors and is
associated with poor survival rates in different breast cancer
cohorts [1, 5]. Considering its involvement in endocrine
resistance further investigation into its potential role as a
therapeutic target is required.
Neoadjuvant and adjuvant chemotherapy in breast cancer
has improved overall survival [51, 52]. However, resistance
to cytotoxic chemotherapy is the main cause of therapeutic
failure and death in women with breast cancer [53, 54].
Bearing in mind the increasing interest of 3D cell culture
systems in cancer research, we sought to investigate and
compare how LMTK3 affects sensitivity to cytotoxic
Fig. 4 Differences in doxorubicin induced global transcriptomic
changes based on LMTK3 expression levels. a Volcano plot showing
the Log2 fold change of genes that respond differently to the doxor-
ubicin treatment in MCF7 and MCF7/LMTK3 cells (Dox:LMTK3).
The Log10 of P value, for signiﬁcance in fold change, is plotted on the
y-axis. b Volcano plot showing the Log2 fold change of doxorubicin
regulated genes in MCF7 cells. Genes are colored based on their mode
of regulation. Genes identiﬁed to respond differently to doxorubicin
treatment in MCF7 and MCF7/LMTK3 cells are colored red (Dox:
LMTK3). In addition, genes regulated commonly by doxorubicin
treatment in both cell lines are colored blue. Genes were colored grey
if their fold change were not signiﬁcantly different compared to
DMSO. c Volcano plot showing the Log2 fold change of doxorubicin
regulated genes in MCF7/LMTK3 cells. Genes are colored based on
their mode of regulation as described above. Top Dox:LMTK3 genes
(based on Log2 fold chage) are labelled on all the volcano plots. d
Heatmap showing amounts by which the read counts of the top-30
Dox:LMTK3 genes (ordered based on Padj value) deviates from the
gene’s average across all the samples. e The UpSet plot showing
common and unique doxorubicin regulated genes signiﬁcantly up (UP)
or down-regulated (DW) in each dataset. The red lines indicate
antagonistic regulation of same genes by doxorubicin across MCF7
and MCF7/LMTK3 cells. The blue lines indicate additive regulation of
genes by doxorubicin across MCF7 and MCF7/LMTK3 cells
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treatment using the 3D models as well as the traditional 2D
monolayers. Our 2D and 3D in vitro assays revealed that
LMTK3 over-expression results in a signiﬁcant increase in
cell viability / proliferation in the presence of doxorubicin.
Despite the high doxorubicin-induced cell death observed in
both parental and LMTK3 overexpressed cell lines, there
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was a clear indication that LMTK3 appears to contribute
resistance to this drug. More importantly, the results were
recapitulated in vivo by examining the antitumor efﬁcacy of
doxorubicin in a breast cancer xenograft tumor model.
Together, these ﬁndings describe a previously undescribed
role of LMTK3 in doxorubicin resistance.
Formation of γH2AX foci starts within seconds after
induction of DSBs, although they may also be present in
small numbers even in the absence of exogenous damage.
This can be due to DNA damage that can occur during
replication, viral infection, senescence, carcinogenic
adducts, exposure to reactive oxygen species and other
cellular processes [55]. In an attempt to investigate the
potential role of LMTK3 in doxorubicin-induced DNA
DSBs, the kinetics of H2AX phosphorylation at Ser139
(γH2AX) foci formation and DNA breaks were measured.
Interestingly, following exposure to doxorubicin, γH2AX
foci formation were initially delayed while the % of DNA in
the tail, reﬂecting the number of DNA breaks [56], was
signiﬁcantly lower in cells over-expressing LMTK3 fol-
lowing exposure to doxorubicin, suggesting that LMTK3 is
implicated in the DNA damage response process.
Following, in order to elucidate the underlying
mechanistic role of LMTK3 in doxorubicin-induced DNA
damage and H2AX phosphorylation, the upstream ATM
kinase was examined. Consistent with previous reports [27–
29], exposure to doxorubicin induced phosphorylation of
ATM at Ser1981 in MCF7 cells. However, phosphorylation
of ATM at Ser1981 was signiﬁcantly impaired in cells
overexpressing LMTK3, which can explain the subsequent
downstream reduction of H2AX Ser139 phosphorylation.
Further investigation in the exact mechanism via which
LMTK3 hinders ATM phosphorylation in response to DNA
damage will provide us with essential information about the
role of LMTK3 in this signaling pathway.
Phosphorylation of KAP1 at Ser824 by ATM, exclu-
sively at DNA lesions, leads to chromatin relaxation and
stimulate cells’ sensitivity to DSB-inducing agents [57, 58].
LMTK3 overexpression decreased KAP1 phosphorylation
at Ser824, at least partly through the interaction with PP1α,
as we have recently described [14]. Our new ﬁndings sug-
gest that the LMTK3-induced decreased KAP1 phosphor-
ylation can also occur (direct or indirectly) as a result of
reduced ATM activity. Taken together, LMTK3 affects the
phosphorylation of KAP1 by keeping it in an active co-
repressor state that delays the induction of DNA damage
and the de-repression of LMTK3-bound tumor suppressor-
like genes (i.e., cell cycle control and apoptosis).
Interestingly, our RNA-seq data revealed that doxor-
ubicin differentially regulated the expression of 784 genes
in MCF7 and MCF7/LMTK3 cells. Of these 784 genes,
SOX6 and HEY1 had a dramatic change in response to
doxorubicin treatment in MCF7 and MCF7/LMTK3 cells. It
is worth remarking that SOX6 [59] and HEY1 [60] are
transcription factors associated with esophageal squamous
cell carcinoma and breast cancer respectively, even though
their roles in breast cancer and chemotherapy have not been
thoroughly deﬁned. Therefore, it would be interesting to
further study their impact in breast cancer development as
well as in chemotherapy resistance. The RNAseq results can
be further used to generate new hypotheses to uncover
additional mechanisms underlying LMTK3 mediated
resistance to chemotherapy. For example, our analysis
found that in MCF7/LMTK3 cells, the overexpression of
LMTK3 affected a large number of Estrogen receptor alpha
(ESR1) target genes (Supplementary excel ﬁles 5 and 6).
Importantly, a signiﬁcant fraction of those genes was
changed in a direction that suggests decrease in
doxorubicin-mediated inhibition of the aryl hydrocarbon
receptor signaling, a pathway known to drive breast cancer
progression. Hence, it would be interesting to validate
whether the activation of aryl hydrocarbon receptor sig-
naling and ESR1 would be sufﬁcient to induce resistance to
doxorubicin. In aggregate, our RNAseq data have revealed
dysregulation in several canonical pathways and upstream
targets that can offer additional insights into the observed
LMTK3-mediated doxorubicin resistance in MCF7 cells.
Finally, in a clinical setting, after analysing pre- and
post-chemotherapy samples from breast cancer patients, we
detected a positive correlation between increased number of
chemotherapy cycles and LMTK3 protein levels. These data
were in accordance with our previous observations
Fig. 5 Functional analysis of doxorubicin-LMTK3 mediated differ-
ential gene expression. a Heatmaps comparing Z scores of canonical
pathways signiﬁcantly enriched for doxorubicin regulated genes
identiﬁed from doxorubicin/DMSO treated MCF7 and MCF7/LMTK3
cells. The signiﬁcant P-values were calculated by Fisher’s exact test.
The activation or inhibition of the canonical pathways and disease bio
functions is given by Z score. A Z score of ≥2 is considered as sig-
niﬁcant activation and a Z-value of ≤−2 is considered as signiﬁcant
inhibition. The Z score between (0, 2) or (−2, 0) represents trend
towards activation or inhibition, respectively. b A bar graph comparing
Z scores of disease biological functions enriched for doxorubicin
regulated genes identiﬁed from doxorubicin/DMSO treated MCF7 and
MCF7/LMTK3 cells. c Functional classiﬁcation of Dox:LMTK3 genes
identiﬁed using PANTHER classiﬁcation system. d–f GO pathways
analysis of the protein-protein interaction clusters identiﬁed in Dox:
LMTK3 genes using fast-greedy algorithm provided with STRING
database. The STRING network analysis was then performed on gene
products involved in RNA processing (d: Cluster 1), DNA repair (e:
Cluster 2), and regulation of cell death (f: Cluster 3). The blue, red and
green color in STRING network of RNA processing represents pro-
teins involved in splicesome, ribosome and ribosome biogenesis
respectively. The red and blue color in STRING network of DNA
repair represents proteins involved in Nucleotide Excision Repair and
Base Excision Repair. The red color in STRING network of regulation
of cell death represents proteins involved in downregulation of
apoptotic pathways. For all the STRING networks, the strength of the
black line indicates strength of the data support for a given protein-
protein association
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demonstrating a tendency of LMTK3 up-regulation with
ongoing neo-adjuvant chemotherapy (doxorubicin / doc-
etaxel) [5]. This intriguing result, in combination with the
already established oncogenic role of LMTK3, requires
further investigation as it suggests that prolonged che-
motherapy might actually have adverse effects for certain
patients. In addition, it will be interesting to elucidate the
mechanism and feedback-loop signaling pathways via
which doxorubicin, with or without docetaxel, promotes the
over-expression of LMTK3, as we have seen in the matched
clinical samples.
In summary, this is the ﬁrst study to establish a new
function of LMTK3 involvement in doxorubicin resistance.
Although there are still many questions to address, our
current data suggest a multifaceted role of LMTK3 in
response to doxorubicin-induced cytotoxicity.
Materials and methods
Cell lines and reagents
MCF7 and MDA-MB-231 breast cancer cell lines (ATCC;
STR authenticated) were maintained in Dulbecco’s Mod-
iﬁed Eagle’s Medium (DMEM, Sigma-Aldrich) supple-
mented with 100 Units/ml penicillin, 100 µg/ml
streptomycin, 2 mM L-glutamine (PSG, Sigma-Aldrich) and
10% heat inactivated fetal bovine serum (FBS, First Link).
Fig. 6 LMTK3 expression in pre
and post-chemotherapy primary
breast tumors. a Representative
histological images of LMTK3
expression in matched pre- and
post-chemotherapy biopsies
(docetaxel and doxorubicin) of a
breast cancer patient from study/
cohort #3. b Scoring of nuclear
LMTK3 expression levels in
individual and pooled breast
cancer cohorts receiving
chemotherapy treatment
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MCF7/LMTK3 and MDA-MB-231/LMTK3, stably over-
expressing LMTK3, were cultured in DMEM supplemented
with 10% FCS, G418 (500 μg/ml; Invitrogen) and 1% PSG.
All cells were incubated at 37 °C in humidiﬁed 5% CO2,
and were frequently tested for mycoplasma contamination.
Antibodies used: LMTK3 (sc-100418, Santa Cruz Bio-
technology); LMTK3 (H00114783-M02, Abnova); β-actin
(ab627, Abcam); phospho-histone H2A.X Ser139 (2577,
Cell Signaling Technology); phospho-histone H2A.X
Ser139 (9718, Cell Signaling Technology); ATM (sc-
23921, Santa Cruz Biotechnology); phospho-ATM Ser1981
(4526, Cell Signaling Technology); KAP1 (ab10484,
Abcam); phospho-KAP1 Ser824 (ab70369, Abcam). Dox-
orubicin hydrochloride (D1515) was purchased from
Sigma-Aldrich.
3D spheroid cultures
3D spheroids were generated from different breast cancer
cell lines (MCF7, MCF7/LMTK3, MDA-MB-231 and
MDA-MB-231/LMTK3) using 96-well round-bottom Ultra
Low Attachment (ULA) plates (Corning®, New York,
USA) that feature a hydrogel layer, which inhibits cellular
attachment. Brieﬂy, using ULA plates, 2.5 × 103 cells/well
were seeded in 30 µl of complete medium. Immediately
after seeding, the plates were centrifuged at 300 × g for
3 min, and maintained at 37 °C in humidiﬁed 5% CO2 for
72 h. Following spheroids formation, 3D cultures were
treated and analyzed accordingly, as described below.
Cells labelling
Cells were collected, counted and resuspended to a ﬁnal
concentration of 1 × 106 in serum free medium. The green
ﬂuorescent, lipophilic carbocyanine SP-DiOC18(3) (3,3′-
dioctadecyl-5,5′-di(4-sulfophenyl) Oxacarbocyanine,
Sodium Salt) (thermoﬁsher) was added to the cell suspen-
sion to a ﬁnal concentration of 1 µM. After 2 h at 37 °C in
humidiﬁed 5% CO2, cells were centrifuged at 300×g for
5 min and cell pellets were washed twice with 1 ml of PBS.
Labelled cells (excitation 475–495 nm, and emission
520–560 nm) were detected using the EVOS Cell Imaging
Systems (thermoﬁsher). Stained cells were used for further
analysis.
Cell viability / proliferation assays
Cell viability was assessed using the CellTiter-Glo assay
(Promega) following the manufacturer’s instructions and
the sulphorhodamine B growth assay, as previously
described [61]. Brieﬂy, 2500–3000 cells were seeded per
well in a 96-well plate and were grown for different time
points in the presence or absence of various concentrations
of doxorubicin. Control cells were treated with DMSO, at
the same dilution as the highest concentration of doxor-
ubicin treatment. Luminescence was recorded with a plate
reader (Promega GloMax Multi Detection System).
Western blotting
Protein lysates were extracted using RIPA buffer (Sigma)
including fresh protease and phosphatase inhibitors and
standard western blotting protocol was performed as
described before [62].
Xenograft mouse model
The study consisted of 4 experimental groups each con-
taining 10 female athymic nude mice (strain: Nude-
Foxn1nu) after randomization. Due to the hormone depen-
dency of the MCF7 and MCF7/LMTK3 cell lines, 17β
estradiol pellets (60 day release) were implanted sub-
cutaneously into the right ﬂank of all participating animals
4 days prior to tumor inoculation (day −4). On day 0, 5 ×
106 MCF7 or GG MCF7/LMTK3 tumor cells, respectively,
in 200 μl Matrigel:PBS 1:1 were implanted into the sub-
cutaneous space of the left ﬂank of 20 animals per cell line.
Following, primary tumor sizes were measured twice
weekly (Monday and Friday) by calipering. On day 10, after
mean tumor volumes had reached approximately 100–200
mm3, animals were randomized into 2 groups per cell line,
each containing 10 animals. On the same day, treatment was
initiated for Groups 2 (MCF7+Dox) and 4 (MCF7/LMTK3
+Dox), whereas animals of Groups 1 (MCF7) and 3
(MCF7/LMTK3) were kept untreated. Animals of Groups 2
and 4 were treated with 8 mg/kg Doxorubicin intravenously
(i.v.) on days 10 and 17. Mice were sacriﬁced on day 28.
Primary tumor tissues of all animals were photographed and
collected and wet weights and volumes determined
accordingly. Tumor volumes were measured every 3 or
4 days using a caliper and calculated using the formula:
W2xL/2 (L= length and W= the perpendicular width of the
tumor. Experimental protocols had been approved by the
Ethics Committee for Animal Experimentation. The
experimental protocol was registered by the Regierung-
spräsidium Freiburg (G-13/23).
Immunoﬂuorescence staining
Cells grown on glass coverslips were ﬁxed in 4% paraf-
ormaldehyde for 10 min, washed in PBS and incubated with
0.3% (v/v) Triton X-100 for 10 min at RT. Following, cells
were washed in PBS and blocked with 10% AB serum in
PBS for 30 min. Coverslips were then incubated overnight
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at 4 °C with primary antibodies, diluted in the same buffer.
Cells then were washed and incubated with Alexa Flour®-
488 secondary anti-rabbit and Alexa Flour®-555 secondary
anti-mouse antibodies (Invitrogen) at RT for 60 min. After
washing, coverslips were mounted onto glass slide in
Mowiol (Calbiochem) with 4′,6-diamidino-2-phenylindole
(DAPI) solution [10% (w/v) Moviol, 1 µg/ml DAPI]. Cov-
erslips were examined on a Leica TCS SP5 II STED laser
scanning confocal microscope (Leica Microsystems).
RNA extraction, library construction, and RNAseq
MCF7 cells and MCF7/LMTK3 cells were treated with 1
μM doxorubicin or DMSO for 24 h in duplicates, and total
RNA was isolated using PureLinkTM RNA Mini Kit
according to manufacturer’s instruction. The RNA samples
were quantitated using a Qubit 2.0 (Life Technologies, Ca,
USA) ﬂuorimeter from Invitrogen with a High Sense RNA
kit to obtain correct starting concentrations. Bioanalyzer
was run using RNA Pico 6000 kit to determine RIN scores
for the samples to assess sample quality. Each sample was
diluted in order to get a ﬁnal mass of 500 ng of RNA in 10
μl of RNase free water. Library prep was performed using
the RNA hyper prep kit with Riboerase from KAPA Bio-
systems (Catalog Number KK8560) according to manu-
facturer’s recommendation. The library fragmentation was
performed at 85 °C for 4.5 min. All Libraries underwent
eight cycles of PCR with the recommended conditions.
NEXTﬂex-96 DNA barcodes from Bio- Scientiﬁc were
ligated to allow for multiplexing of samples. After library
preparation, each sample was quantitated using the Qubit
DNA High Sense Kit, then dilutions were performed to
equalize each library to 3 ng/μl. Diluted libraries were then
run on the Bioanalyzer using DNA High Sense kit to
determine library molarities. Libraries were pooled which
was then diluted to a ﬁnal concentration of 2 nM. Pooled
and diluted library was denatured and diluted for sequen-
cing with a 1% PhiX spike-in by following the Illumina
guide. Library was loaded onto the Nextseq 500 and
sequencing was performed using a 75-cycle high output v2
kit.
Comet assay
DSB repair was analysed by neutral comet assay using the
Trevigen comet assay kit (4250-050-K) according to the
manufacturer’s methods. 2 h after doxorubicin treatment,
cells were subjected to comet analysis at the indicated time
points. Cell suspensions (1 × 105 cells in 50 µl PBS) were
mixed with 450 µl of heated LM-Agarose at 37°C and were
spread on the slides covered with agarose and allowed to
solidify at 4 °C in a moist box. After a clear ring appears at
edge, the slides were immersed in freshly prepared cold
(4 °C) lysis solution overnight at 4 °C. The slides were
removed from the lysis buffer, drained the excess buffer and
transferred to an electrophoresis chamber. After equilibrated
in cold 1 × neutral electrophoresis solution for 30 min, SDS-
PAGE electrophoresis was conducted at 18 V for 45 min.
The slides were then immersed in DNA Precipitation
Solution for 30 min, followed by 70% ethanol for another
30 min at RT. The slides were drained and air-dried for
more than 15 min. After staining with DAPI, comet images
were captured by ﬂuorescence microscopy. The tail moment
was quantiﬁed using the ImageJ software with OpenComet
plug-in [63].
Raw data processing, alignment analysis, and
identiﬁcation of differentially expressed genes
High-quality clean reads were obtained after trimming the
adapter sequences and removing invalid reads containing
poly-N and low-quality reads from the raw data using the
fastX tool kit (v 0.0.14) (http://hannonlab.cshl.edu/fastx_
toolkit/license.html). The quality of reads was conﬁrmed
using the fastqc tool kit (v 0.11.5) (http://www.bioinforma
tics.babraham.ac.uk/projects/fastqc/). The downstream ana-
lyses were conducted using the high-quality clean reads.
The clean reads were mapped to the ENSEMBL built
GRCH37 using the STAR aligner (v2.5.3a) [64] with
default parameters along with the ENCODE options as
described in the STAR manual. We then estimated the read
counts for each gene using the summarize Overlaps func-
tion provided with the R package DESeq2 [65]. Subse-
quently, we identiﬁed differentially expressed genes
(DEGs) using DESeq2 interaction design model. The
Benjamini-Hochberg corrected P value (Padj ≤ 0.05) and
Log2 fold change ≥ |1| were used as the threshold to screen
signiﬁcance of DEGs.
Quantitative real time PCR (qRT-PCR)
Total cellular RNA was extracted from cells using the
PureLinkTM RNA Mini Kit (Invitrogen) according to man-
ufacturer recommendations (including DNAse treatment
step). Complementary DNA synthesis reactions were per-
formed with 2.5 ug of RNA using SuperScript III First-
Strand Synthesis System (Invitrogen) according to manu-
facturer instruction. cDNA samples were ampliﬁed using
SYBR Green PCR Master Mix on the Applied Biosystems
7500 Detection System. Each PCR reaction had three
technical replicates and three biological replicates. Gene-
speciﬁc forward and reverse primers are detailed in Sup-
plementary Table 5. Furthermore, speciﬁcity and efﬁciency
for primers were analyzed as we have previously reported
[66]. The ampliﬁed transcripts were quantiﬁed using the
comparative ddCT method.
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Functional annotation of DEGs
The analyses of canonical pathways, disease, and biological
functions, as well as upstream regulators of DEGs was
conducted using the Ingenuity Pathway (https://www.qia
genbio-informatics.com/products/ingenuity-pathway-ana
lysis). The protein classiﬁcation of the DEGs was per-
formed using PANTHER version 11 [67]. The GO anno-
tation analyses of gene sets were performed using www.
geneontology.org [68, 69]. The protein-protein interaction
analyses of gene sets were performed using the R package
STRING protein-protein interaction database [70].
Clinical specimens
Pre- and post-chemotherapy primary breast tumor pairs
from 148 patients were stained for LMTK3. All patients had
newly diagnosed, histologically or cytologically conﬁrmed
breast cancer and were enrolled into one of four therapeutic
clinical studies that were approved by the institutional ethics
committee, evaluating primary and pre-operative che-
motherapy. In study 1 (n= 65), patients received 6 cycles of
alternating sequential doxorubicin (A) and docetaxel (T)
3 weekly and were randomized to start either with doxor-
ubicin or docetaxel (A →T→A→T→A→T or
T→A→T→A→T→A). In study 2 (n= 31), patients were
treated with 4 cycles of docetaxel modulated with oral
ketoconazole, 3 weekly. In study 3 (n= 25), patients were
randomized to 4 cycles of doxorubicin or 4 cycles of doc-
etaxel, 3 weekly. In study 4 (n= 27), patients were treated
with 4 cycles of doxorubicin and cyclophosphamide,
3 weekly, with or without low-dose sunitinib. Tumor
biopsies were taken at baseline and after cycle 1 che-
motherapy in all four studies; one additional tumor biopsy
after 4 cycles of chemotherapy was obtained in studies 1
and 4. Written informed consent was obtained from all
subjects enrolled into these studies 1–4. The ethics com-
mittee that approved the study conduct was the National
Healthcare Group Domain Speciﬁc Review board. Clinical
trial registration numbers: study 1 (NCT00212082), study 2
(NCT00212095), study 3 (NCT00669773), study 4
(NCT02790580).
Immunohistochemistry
Immunohistochemistry staining for LMTK3 was performed
and nuclear staining was scored as previously described [1,
5]. Paired t test was applied to determine the difference in
LMTK3 expression between matched pre and post-
treatment tumors. All statistical analyses were performed
using the IBM SPSS package (version 19.0 for Windows,
IBM SPSS Inc., USA) with signiﬁcance set at the 5% level.
Statistics
All data are expressed as means ± standard error of the
mean (SEM). Data were analysed by paired Student’s t-test
and/or two-way ANOVA test, using GraphPad Prism 7.00
(GraphPad Software, Inc., San Diego, USA).
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